Clinical Trials Directory

Trials / Completed

CompletedNCT04881942

Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users

Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users During Use of Four e-Vapor Products

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Altria Client Services LLC · Industry
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products. The study will enroll approximately 32 adult e-vapor-using subjects at one site in the United States in High Point, NC.

Detailed description

This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products (which are no longer manufactured or sold commercially). The study will enroll approximately 32 adult e-vapor-using (with no more that 60% of either sex). Each of the 32 subjects will provide two exhaled breath samples (10 puffs for each sample) for all four test products. Subjects will make two visits to the site, one screening visit and one 4 day in-clinic visit to provide exhalation samples for four test products (one each day for 4 days). Subjects will also use their assigned test product ad libitum for 12 hours each day after the collection of exhaled breath samples. Subjects will be randomly assigned to a test product-use schedule at Visit 2, with one test product used per day. The anticipated study duration for each subject from screening through completion of all study participation will be approximately 34 days.

Conditions

Interventions

TypeNameDescription
OTHERe-Vapor Product Ae-Vapor product XL25F
OTHERe-Vapor Product Be-Vapor product XL40CB
OTHERe-Vapor Product Ce-Vapor product XL35WM
OTHERe-Vapor Product De-Vapor product XL40MB

Timeline

Start date
2017-03-27
Primary completion
2017-04-21
Completion
2018-01-26
First posted
2021-05-11
Last updated
2024-07-30
Results posted
2024-07-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04881942. Inclusion in this directory is not an endorsement.